Bear Stearns Healthcare Conference In Brief
One Swiss pharma company?: Novartis continues "to indicate to Roche that it might be a good idea for us to sit down and talk and I think as late as last Sunday, the Roche CEO continues to say that it's absolutely out of the question and not on the table," General Manager Kurt Graves says during Bear Stearns healthcare conference in New York City Sept. 17. "I would say it's remained consistent for over a year." Novartis' purchase of a 20% stake in Roche a year ago sparked rumors that Novartis was interested in partnering with its Swiss neighbor (1"The Pink Sheet" May 14, 2001, p. 11)...
You may also be interested in...
Pfizer's post-merger plans for Celebrex include a second gastrointestinal outcomes study to demonstrate a safety benefit for the COX-2 inhibitor
The approval of Novartis' Zelnorm reflects FDA's comfort with an active surveillance program proposed by the company - and the extensive post marketing safety database of the irritable bowel syndrome agent in overseas markets
Novartis is riding high expectations for the COX-2 inhibitor Prexige to a new level of prestige on Wall Street